journal article·2024-07Open access

Angiogenesis‐Enabled Human Ovarian Tumor Microenvironment‐Chip Evaluates Pathophysiology of Platelets in Microcirculation

Lopamudra D. Ghosh, Tanmay Mathur, James J. Tronolone, Ashley Chuong, Kelly Rangel, Sara Corvigno, Anil K. Sood, Abhishek Jain

Advanced Healthcare Materials· Volume 13· Issue 19

Abstract

Abstract The tumor microenvironment (TME) promotes angiogenesis for its growth through the recruitment of multiple cells and signaling mechanisms. For example, TME actively recruits and activates platelets from the microcirculation to facilitate metastasis, but platelets may simultaneously also support tumor angiogenesis. Here, to model this complex pathophysiology within the TME that involves a signaling triad of cancer cells, sprouting endothelial cells, and platelets, an angiogenesis‐enabled tumor microenvironment chip (aTME‐Chip) is presented. This platform recapitulates the convergence of physiology of angiogenesis and platelet function within the ovarian TME and describes the contribution of platelets in promoting angiogenesis within an ovarian TME. By including three distinct human ovarian cancer cell‐types, the aTME‐Chip quantitatively reveals the following outcomes—first, introduction of platelets significantly increases angiogenesis; second, the temporal dynamics of angiogenic signaling is dependent on cancer cell type; and finally, tumor‐educated platelets either activated exogenously by cancer cells or derived clinically from a cancer patient accelerate tumor angiogenesis. Further, analysis of effluents available from aTME‐Chip validate functional outcomes by revealing changes in cytokine expression and several angiogenic and metastatic signaling pathways due to platelets. Collectively, this tumor microphysiological system may be deployed to derive antiangiogenic targets combined with antiplatelet treatments to arrest cancer metastasis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Angiogenesis and VEGF in Cancer · Inflammatory Biomarkers in Disease Prognosis · Platelet Disorders and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering College of Engineering Texas A&M University College Station TX 77843 USA

Department of Gynecologic Oncology and Reproductive Medicine UT MD Anderson Cancer Center Houston TX 77030 USA

Department of Medical Physiology College of Medicine Texas A&M Health Science Center Bryan TX 77807 USA

Department of Cardiovascular Sciences Houston Methodist Academic Institute Houston TX 77030 USA

Funding

National Institutes of Health · Ovarian Cancer Research Fund Alliance · Frank McGraw Memorial Chair in Cancer Research · National Science Foundation · National Heart, Lung, and Blood Institute

References (52)

Show source-provided references
1. 10.1038/nm0603-65310.1038/nm0603-653 ↗
2. 10.1038/nrclinonc.2011.2110.1038/nrclinonc.2011.21 ↗
3. Ma S. · Biochim. Biophys. Acta – Rev. Cancer · 2018 · 7 · 326
4. 10.4103/ijmr.IJMR_1435_1910.4103/ijmr.IJMR_1435_19 ↗
5. 10.1007/s11864-014-0318-010.1007/s11864-014-0318-0 ↗
6. 10.1172/JCI8508610.1172/JCI85086 ↗
7. 10.3389/fimmu.2022.80284610.3389/fimmu.2022.802846 ↗
8. 10.1016/j.ceca.2018.11.00510.1016/j.ceca.2018.11.005 ↗
9. 10.1055/s-0038-167514910.1055/s-0038-1675149 ↗
10. 10.1371/journal.pone.002612510.1371/journal.pone.0026125 ↗
11. 10.1172/JCI20042212310.1172/JCI200422123 ↗
12. 10.1182/blood-2009-10-24729610.1182/blood-2009-10-247296 ↗
13. 10.1053/j.seminoncol.2014.04.00410.1053/j.seminoncol.2014.04.004 ↗
14. 10.1056/NEJMoa111035210.1056/NEJMoa1110352 ↗
15. 10.1007/s10555-014-9498-010.1007/s10555-014-9498-0 ↗
16. 10.1007/BF0130717810.1007/BF01307178 ↗
17. 10.1016/S0049-3848(01)00285-710.1016/S0049-3848(01)00285-7 ↗
18. 10.1002/ajh.2173210.1002/ajh.21732 ↗
19. Verheul H. M. · Clin. Cancer Res. · 2000 · 6 · 166
20. 10.1046/j.1365-2141.2003.04773.x10.1046/j.1365-2141.2003.04773.x ↗
21. 10.1080/09537104.2023.224748910.1080/09537104.2023.2247489 ↗
22. 10.1002/cpt.105410.1002/cpt.1054 ↗
23. 10.1002/cpt.74210.1002/cpt.742 ↗
24. 10.1073/pnas.171860011510.1073/pnas.1718600115 ↗
25. 10.1021/acsami.6b0874610.1021/acsami.6b08746 ↗
26. 10.1002/adhm.20170125710.1002/adhm.201701257 ↗
27. 10.1038/nprot.2017.01810.1038/nprot.2017.018 ↗
28. 10.1073/pnas.141711511210.1073/pnas.1417115112 ↗
29. 10.1039/c3lc41320a10.1039/c3lc41320a ↗
30. 10.1038/ncomms1017610.1038/ncomms10176 ↗
31. 10.1007/s10544-016-0095-610.1007/s10544-016-0095-6 ↗
32. 10.1182/bloodadvances.202000163210.1182/bloodadvances.2020001632 ↗
33. 10.1126/sciadv.abg528310.1126/sciadv.abg5283 ↗
34. 10.1038/nrdp.2016.6110.1038/nrdp.2016.61 ↗
35. 10.1002/advs.20190087810.1002/advs.201900878 ↗
36. 10.2217/rme-2016-015210.2217/rme-2016-0152 ↗
37. 10.1182/blood.V96.1.3410.1182/blood.V96.1.34 ↗
38. 10.1074/jbc.M40393720010.1074/jbc.M403937200 ↗
39. 10.1016/j.bbrc.2003.11.01710.1016/j.bbrc.2003.11.017 ↗
40. 10.1073/pnas.122152611010.1073/pnas.1221526110 ↗
41. 10.1016/j.jbiomech.2015.10.02610.1016/j.jbiomech.2015.10.026 ↗
42. 10.1111/micc.1261810.1111/micc.12618 ↗
43. 10.1038/srep4583510.1038/srep45835 ↗
44. 10.1083/jcb.20130706710.1083/jcb.201307067 ↗
45. 10.21037/atm-20-449710.21037/atm-20-4497 ↗
46. 10.1186/s12943-021-01347-110.1186/s12943-021-01347-1 ↗
47. Varkey J. · Cureus · 2021 · 13
48. 10.1016/j.ccell.2014.10.00610.1016/j.ccell.2014.10.006 ↗
49. 10.1371/journal.pone.007147210.1371/journal.pone.0071472 ↗
50. 10.7554/eLife.5074010.7554/eLife.50740 ↗
51. 10.1039/D0LC01186J10.1039/D0LC01186J ↗
52. 10.1038/s41467-017-00411-z10.1038/s41467-017-00411-z ↗